<DOC>
	<DOC>NCT01614769</DOC>
	<brief_summary>This study aims to assess how glimepiride affects the recovery from hypoglycemia in participants with type 2 diabetes mellitus. The primary objective is to estimate the time taken by participants to recover from hypoglycemia to euglycemia after treatment with either 2 mg or 4 mg of glimepiride when compared to placebo.</brief_summary>
	<brief_title>Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus (MK-0000-253)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Has clinically confirmed diagnosis of type 2 diabetes mellitus (T2DM) controlled by diet and exercise alone, or treated by metformin only with same dose for &gt;= 12 weeks prior to screening visit. Females of reproductive potential who demonstrate nongravid state, agree to use (and/or have partner use) two acceptable methods of birth control starting at least two weeks prior to study, throughout study, and at least two weeks after last dose of study drug. Females of nonreproductive potential, post menopausal, status post hysterectomy, oophorectomy or tubal ligation. Is in good health, other than T2DM. Has been a nonsmoker and/or non user of nicotinecontaining products for the previous 6 months. If discontinued use for previous 3 months, may be enrolled at investigator's discretion. Will follow American Heart Association weight maintaining diet and exercise program or equivalent beginning 2 weeks prior to study until poststudy visit. At screening visit has a Body Mass Index (BMI) =&lt; 40 kg/m^2. At screening visit has a Hemoglobin A1c (HbA1c) of &gt;= 7% and &lt; 10% (+/ 0.1%). On the morning of randomization at predose has fasting plasma glucose (FPG) &gt;= 126 mg/dL, and =&lt; 250 mg/dL. Has a history of stroke, chronic seizures, or major neurological disorder. Has a history of any illness that might confound the results of the study or pose additional risk to the participant. Has a history of type 1 diabetes mellitus, ketoacidosis, Cpeptide =&lt; 0.8 ng/mL, secondary forms of diabetes or diabetic complications. Has a history of neoplastic disease. Is a nursing mother. Has been treated =&lt; one year of screening visit with sulfonylurea agents, meglitinides, dipeptidyl peptidase4 (DPP4) inhibitors, glucagonlike peptide1 (GLP1) analogs, or insulin. Has received treatment within =&lt; 12 weeks of screening visit with a peroxisome proliferatoractivated receptor γ (PPARγ) agonist. Is taking medications for a comorbid condition or anticipates taking new medications beginning 2 weeks prior to study. Consumes excessive amounts of alcohol or caffeinated beverages. Is a regular user of illicit drugs, or has a history of drug abuse within the previous 6 months. Has had major surgery, lost 500 mL of blood, or participated in another investigational study within 4 weeks prior to screening visit. Is on a weight loss program, but not in the maintenance phase, or treated with a weight loss medication within 8 weeks of prestudy visit. Has a history of severe allergies, anaphylactic reaction or intolerability to drugs, food, insulin, glimepiride or sulfonamide derivatives.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>